Prognostic factors and risk stratification in chronic lymphocytic leukemia

Seminars in Oncology

Volumn 43, Issue 2, 2016, Pages 233-240

  Parikh, Sameer A ^a   Shanafelt, Tait D ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cytogenetics; IGHV mutation; Next generation sequencing; Outcomes

Indexed keywords

ADAM29 PROTEIN; ALPHA4 INTEGRIN; ATM PROTEIN; B LYMPHOCYTE RECEPTOR; B RAF KINASE; BETA 2 MICROGLOBULIN; BIRC3 PROTEIN; CD38 ANTIGEN; CLLU1 PROTEIN; DDX3X PROTEIN; FBXW7 PROTEIN; LIPOPROTEIN LIPASE A; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MYELOID DIFFERENTIATION FACTOR 88; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE ZAP 70; PROTEIN MCL 1; PROTEIN P53; RETINOBLASTOMA PROTEIN; SF3B1 PROTEIN; THROMBOPOIETIN; THYMIDINE KINASE; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; BIOLOGICAL MARKER;

CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; LEUKEMOGENESIS; META ANALYSIS (TOPIC); NEXT GENERATION SEQUENCING; ONCOGENE K RAS; ONCOGENE N RAS; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; REVIEW; SERUM; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; DISEASE COURSE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MORTALITY; MUTATION; PROGNOSIS; TREATMENT OUTCOME;

BIOMARKERS; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; PROGNOSIS; TREATMENT OUTCOME;

EID: 84960510182     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2016.02.009     Document Type: Review

References (79)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 Cancer J Clin 64 1 2014 9 29
2. T.D. Shanafelt Predicting clinical outcome in CLL: How and why Hematology/Education Program of the American Society of Hematology American Society of Hematology Education Program 2009 421 429
3. K.R. Rai, A. Sawitsky, E.P. Cronkite, A.D. Chanana, R.N. Levy, and B.S. Pasternack Clinical staging of chronic lymphocytic leukemia Blood 46 2 1975 219 234
4. J.L. Binet, A. Auquier, G. Dighiero, and et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis Cancer 48 1 1981 198 206
5. S. Molica, and A. Alberti Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia Cancer 60 11 1987 2712 2716
6. C. Rozman, E. Montserrat, J.M. Rodriguez-Fernandez, and et al. Bone marrow histologic pattern - the best single prognostic parameter in chronic lymphocytic leukemia: A multivariate survival analysis of 329 cases Blood 64 3 1984 642 648
7. M.A. Bergmann, B.F. Eichhorst, R. Busch, and et al. Early and risk-adapted therapy with fludarabine in high-risk Binet stage A CLL patients prolongs progression free survival but not overall survival: Results of the CLL1 Protocol of the German CLL Study Group (GCLLSG) ASH Annual Meeting Abstracts 110 11 2007 2038
8. W.G. Wierda, S. O'Brien, X. Wang, and et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia Blood 109 11 2007 4679 4685
9. M. Hallek, L. Wanders, M. Ostwald, and et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma Leuk Lymphoma 22 5-6 1996 439 447
10. N. Pflug, J. Bahlo, T.D. Shanafelt, and et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia Blood 124 1 2014 49 62
11. A.M. Tsimberidou, C. Tam, W. Wierda, S. O'Brien, S. Lerner, and M.J. Keating Beta-2 microglobulin (B2M) is an independent prognostic factor for clinical outcomes in patients with CLL treated with frontline fludarabine, cyclophosphamide, and rituximab (FCR) regardless of age, creatinine clearance (CrCl) ASCO Meeting Abstracts 25 18 suppl 2007 7034
12. C. Matthews, M.A. Catherwood, T.C. Morris, and et al. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression Eur J Haematol 77 4 2006 309 317
13. F. Di Raimondo, R. Giustolisi, S. Lerner, and et al. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine Ann Oncol 12 5 2001 621 625
14. R.N. Damle, T. Wasil, F. Fais, and et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia Blood 94 6 1999 1840 1847
15. T.J. Hamblin, Z. Davis, A. Gardiner, D.G. Oscier, and F.K. Stevenson Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia Blood 94 6 1999 1848 1854
16. M. Crespo, F. Bosch, N. Villamor, and et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia N Engl Med 348 18 2003 1764 1775
17. L.Z. Rassenti, S. Jain, M.J. Keating, and et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia Blood 112 5 2008 1923 1930
18. A. Wiestner, A. Rosenwald, T.S. Barry, and et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile Blood 101 12 2003 4944 4951
19. J. Durig, H. Nuckel, M. Cremer, and et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia Leukemia 17 12 2003 2426 2434
20. S. Ibrahim, M. Keating, K.A. Do, and et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia Blood 98 1 2001 181 186
21. R. Claus, D.M. Lucas, A.S. Ruppert, and et al. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia Blood 124 1 2014 42 48
22. Rituximab and bendamustine hydrochloride rai, or ibrutinib alone in treating older patients with previously untreated chronic lymphocytic leukemia. www.clinicaltrials.gov. Last accessed January 12, 2015.
23. T.D. Shanafelt, S.M. Geyer, N.D. Bone, and et al. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: A prognostic parameter with therapeutic potential Br J Haematol 140 5 2008 537 546
24. P. Bulian, T.D. Shanafelt, C. Fegan, and et al. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia J Clin Oncol 32 9 2014 897 904
25. G. Juliusson, D.G. Oscier, M. Fitchett, and et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities N Engl J Med 323 11 1990 720 724
26. H. Döhner, S. Stilgenbauer, A. Benner, and et al. Genomic aberrations and survival in chronic lymphocytic leukemia N Engl J Med 343 26 2000 1910 1916
27. T.D. Shanafelt, T.E. Witzig, S.R. Fink, and et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia J Clin Oncol 24 28 2006 4634 4641
28. S. Stilgenbauer, S. Sander, L. Bullinger, and et al. Clonal evolution in chronic lymphocytic leukemia: Acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival Haematologica 92 9 2007 1242 1245
29. A. Janssens, N. Van Roy, B. Poppe, and et al. High-risk clonal evolution in chronic B-lymphocytic leukemia: Single-center interphase fluorescence in situ hybridization study and review of the literature Eur J Haematol 89 1 2012 72 80
30. C.S. Tam, T.D. Shanafelt, W.G. Wierda, and et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: The M. D. Anderson and Mayo Clinic experience Blood 114 5 2009 957 964
31. T. Zenz, A. Krober, K. Scherer, and et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: Results from a detailed genetic characterization with long-term follow-up Blood 112 8 2008 3322 3329
32. D. Rossi, M. Cerri, C. Deambrogi, and et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: Implications for overall survival and chemorefractoriness Clin Cancer Res 15 3 2009 995 1004
33. T. Zenz, B. Eichhorst, R. Busch, and et al. TP53 mutation and survival in chronic lymphocytic leukemia J Clin Oncol 28 29 2010 4473 4479
34. D. Gonzalez, P. Martinez, R. Wade, and et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: Results from the LRF CLL4 trial J Clin Oncol 29 16 2011 2223 2229
35. L. Wang, M.S. Lawrence, Y. Wan, and et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia N Engl J Med 365 26 2011 2497 2506
36. X.S. Puente, M. Pinyol, V. Quesada, and et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia Nature 475 7354 2011 101 105
37. D. Rossi, S. Rasi, G. Fabbri, and et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia Blood 119 2 2012 521 529
38. P. Sportoletti, S. Baldoni, L. Cavalli, and et al. NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL Br J Haematol 151 4 2010 404 406
39. D. Rossi, V. Spina, R. Bomben, and et al. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia Blood 121 24 2013 4902 4905
40. S. Stilgenbauer, A. Schnaiter, P. Paschka, and et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: Results from the CLL8 trial Blood 123 21 2014 3247 3254
41. V. Quesada, L. Conde, N. Villamor, and et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia Nat Genet 44 1 2012 47 52
42. D.G. Oscier, M.J. Rose-Zerilli, N. Winkelmann, and et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial Blood 121 3 2013 468 475
43. E. Braggio, N.E. Kay, S. VanWier, and et al. Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse Leukemia 26 7 2012 1698 1701
44. D.A. Landau, S.L. Carter, P. Stojanov, and et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia Cell 152 4 2013 714 726
45. D. Rossi, H. Khiabanian, V. Spina, and et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia Blood 123 14 2014 2139 2147
46. G.A. Calin, M. Ferracin, A. Cimmino, and et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia N Engl J Med 353 17 2005 1793 1801
47. T. Zenz, J. Mohr, E. Eldering, and et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia Blood 113 16 2009 3801 3808
48. A. Ferrajoli, T.D. Shanafelt, C. Ivan, and et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia Blood 122 11 2013 1891 1899
49. M. Mraz, L. Chen, L.Z. Rassenti, and et al. miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1 Blood 124 1 2014 84 95
50. R. Visone, A. Veronese, L.Z. Rassenti, and et al. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia Blood 118 11 2011 3072 3079
51. V. Fulci, S. Chiaretti, M. Goldoni, and et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia Blood 109 11 2007 4944 4951
52. H. Ling, M. Fabbri, and G.A. Calin MicroRNAs and other non-coding RNAs as targets for anticancer drug development Nat Rev Drug Disc 12 11 2013 847 865
53. K. Stamatopoulos, C. Belessi, C. Moreno, and et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations Blood 109 1 2007 259 270
54. A. Agathangelidis, N. Darzentas, A. Hadzidimitriou, and et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: A molecular classification with implications for targeted therapies Blood 119 19 2012 4467 4475
55. A. Agathangelidis, A. Vardi, P. Baliakas, and K. Stamatopoulos Stereotyped B-cell receptors in chronic lymphocytic leukemia Leuk Lymphoma 55 10 2014 2252 2261
56. F. Murray, N. Darzentas, A. Hadzidimitriou, and et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: Implications for the role of antigen selection in leukemogenesis Blood 111 3 2008 1524 1533
57. S.A. Parikh, K.G. Rabe, T.G. Call, and et al. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): A cohort study of newly diagnosed patients Br J Haematol 162 6 2013 774 782
58. J.C. Strefford, L.A. Sutton, P. Baliakas, and et al. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: The case of SF3B1 and subset #2 Leukemia 27 11 2013 2196 2199
59. S. Al-Harbi, B.T. Hill, S. Mazumder, and et al. An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737 Blood 118 13 2011 3579 3590
60. D. Heintel, D. Kienle, M. Shehata, and et al. High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia Leukemia 19 7 2005 1216 1223
61. K. Maloum, C. Settegrana, E. Chapiro, and et al. IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide Ann Hematol 88 12 2009 1215 1221
62. P. Oppezzo, Y. Vasconcelos, C. Settegrana, and et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia Blood 106 2 2005 650 657
63. T.T. Lin, K. Norris, N.H. Heppel, and et al. Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease Br J Haematol 167 2 2014 214 223
64. P. Josefsson, C.H. Geisler, H. Leffers, and et al. CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia Blood 109 11 2007 4973 4979
65. A.K. Ghosh, C.R. Secreto, T.R. Knox, W. Ding, D. Mukhopadhyay, and N.E. Kay Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: Implications for disease progression Blood 115 9 2010 1755 1764
66. S. Molica, G. Vitelli, D. Levato, G.M. Gandolfo, and V. Liso Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia Br J Haematol 107 3 1999 605 610
67. T.D. Shanafelt, G. Jenkins, T.G. Call, and et al. Validation of a new prognostic index for patients with chronic lymphocytic leukemia Cancer 115 2 2009 363 372
68. N. Kutsch, J. Bahlo, J.C. Byrd, and et al. The International Prognostic Index for patients with CLL (CLL-IPI): Sn international meta-analysis J Clin Oncol 33 suppl 2015 abstr 7002
69. A. Krober, T. Seiler, A. Benner, and et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia Blood 100 4 2002 1410 1416
70. Applied logistic regression (ed 2) D. Hosmer, and S. Lemeshow 2000 John Wiley & Sons New York, NY
71. Kutsch N, Bahlo J, Byrd JC, et al. The International Prognostic Index for patients with CLL (CLL-IPI): An international meta-analysis. J Clin Oncol 2015;33 (suppl; abstr 7002).
72. M. Hallek, K. Fischer, G. Fingerle-Rowson, and et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial Lancet 376 9747 2010 1164 1174
73. X.C. Badoux, M.J. Keating, X. Wang, and et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL Blood 117 11 2011 3016 3024
74. S. O'Brien, J.A. Jones, S. Coutre, and et al. Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: Results from the phase II RESONATE™-17 trial Blood 124 21 2014 327
75. A.C. Rawstron, N. Villamor, M. Ritgen, and et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia Leukemia 21 5 2007 956 964
76. M. Hallek, B.D. Cheson, D. Catovsky, and et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines Blood 111 12 2008 5446 5456
77. P. Strati, M.J. Keating, S.M. O'Brien, and et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL 2014 123
78. S. Böttcher, M. Ritgen, K. Fischer, and et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: A multivariate analysis from the randomized GCLLSG CLL8 trial J Clin Oncol 30 9 2012 980 988
79. C.S. Tam, S. O'Brien, W. Wierda, and et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia Blood 112 4 2008 975 980